Introduction
Under normal physiological conditions, collagen-rich fibroblasts maintain tissue architecture and serve as a barrier to epithelial cell migration. However, cancer cells have the ability to convert the surrounding fibroblasts into activated CAFs, which secrete specific collagens, growth factors, and enzymes that promote cancer growth, angiogenesis, invasion, and metastasis [1] [2] [3] . At the same time, these CAFs suppress anticancer immunity, confer drug resistance and/or limit the access of chemotherapies, anti-angiogenic therapies, and immunotherapies [1] [2] [3] . Although the exact mechanisms by which activated CAFs contribute to such diverse aspects of cancer progression are unclear, it is thought that fibroblasts together with increased collagen deposition and altered extracellular matrix (ECM) remodeling serve as a rich depot of cancerpromoting growth factors, cytokines, and chemokines [1, 2] . Additionally, altered levels of enzymes responsible for collagen cross-link formation, such as lysyl oxidase (LOX) [4] , increase tissue stiffness and modify mechanotransduction resulting in the reorganization of loose connective tissue into tense linear tracks of fibers that serve as highways to promote chemotaxis of cancer cells [5, 6] .
Recognizing the crucial role of CAFs in most aspects of cancer progression, it has been proposed that rational anticancer therapy design should not only target the cancer cells but also the CAFs [7, 8] . Unlike cancer cells, CAFs are genetically stable [9] , which reduce the risk of therapy-induced clonal selection, resistance, and cancer recurrence. Furthermore, targeting CAFs could potentially affect multiple biochemical pathways to prevent cancer progression and recurrence. CAF-targeting therapeutic approaches in different experimental mouse cancer models have been shown to improve Abbreviations: αSMA, α-smooth muscle actin; CAFs, cancer-associated fibroblasts; CSPG4, chondroitin sulfate proteoglycan 4; ECM, extracellular matrix; LOX, lysyl oxidase; EMT, epithelial-mesenchymal transition; FAP, fibroblast activation protein; PALLD, palladin; PDGFRα, platelet-derived growth factor receptor α; PDPN, podoplanin; TGFβ, transforming growth factor β; TNC, tenascin-C; PRECOG, PREdiction of Clinical Outcomes from Genomic Profiles.tumoral immune response, intratumoral drug delivery, and therapeutic efficacy [10] [11] [12] [13] [14] [15] . These studies confirm the key role of CAFs in cancer progression and demonstrate their effectiveness as a therapeutic target. However, targeting CAFs in some cancer models actually promoted cancer progression. For example, depletion of αSMA+ stroma in a mouse pancreatic cancer model resulted in increased cancer aggressiveness, enhanced hypoxia and epithelialmesenchymal transition (EMT), suppressed anticancer immunity, and reduced survival [16] .
The contradictory results in different cancer models could be explained by different roles of CAFs in different cancer types, i.e. CAFs could be promoting breast cancer and inhibiting pancreatic cancer. Alternatively, in all cancer types CAFs prevent cancer progression until they receive activating signals from cancer cells and convert into 'activated CAFs', which in turn confer invasive and metastatic abilities upon cancer cells [7] . Therapies that target all CAFs are counterproductive and likely to result in the death of normal fibroblasts and significant toxicity. Preferential targeting of activated CAFs has been challenging because activated CAFs are poorly understood at the molecular level. During activation, CAFs exhibit phenotypic changes that partially overlap with myofibroblastic changes during wound healing, inflammation, and fibrosis, including secretion of specific ECM components, cytokines and growth factors [1, 17] . Several markers have been used to distinguish activated from nonactivated CAFs: α-smooth muscle actin (αSMA, encoded by gene ACTA2) [3] , fibroblast activation protein (FAP) [12] , podoplanin (PDPN) [18] , palladin (PALLD) [19, 20] , tenascin-C (TNC) [21] , plateletderived growth factor receptor α (PDGFRα) [22, 23] , and chondroitin sulfate proteoglycan 4 (CSPG4) [24] . However, these markers are frequently expressed in other cells within the cancer stroma, such as vascular smooth muscle cells, pericytes, and mesenchymal stem cells. This lack of specificity could pose problems in therapeutic targeting and underscores the need to better understand the molecular characteristics of activated CAFs in order to develop more precise and less toxic targeted therapies.
COL11A1 encodes the α1 chain of collagen XI, a minor fibrillar collagen expressed by chondrocytes and osteoblasts but not quiescent fibroblasts [25, 26] . The absence of functional collagen XI leads to abnormally thickened cartilage and tendon fibrils, suggesting the role of collagen XI in maintaining proper fibril diameter [27, 28] . Studies have demonstrated that COL11A1 mRNA is markedly elevated in cancers of the oral cavity/pharynx, head and neck, breast, lung, esophagus, stomach, pancreas, colon, and ovary, but not in matched normal tissues (reviewed in [25, 26] ). COL11A1 has been identified as part of gene signatures associated with adverse clinical outcomes including resistance to neoadjuvant therapy in breast cancer [29] , time to recurrence in glioblastoma [30] , poor survival in kidney cancer [31] , and time to recurrence and overall survival in ovarian cancer [32, 33] . In situ hybridization in ovarian cancer and immunohistochemistry in pancreatic cancer revealed that COL11A1 mRNA and pro-protein are primarily expressed in CAFs [25, 32] . The restricted expression of COL11A1 in normal tissues and its enrichment in CAFs during cancer progression combined with its association with adverse clinical outcomes in multiple types of cancer support its candidacy as a specific marker of fibroblast activation in diverse cancers. Here, we explore the suitability of COL11A1 as a pan-cancer marker of activated CAFs and use it as a 'seed' to identify the transcription signature of activated CAFs in 13 epithelial cancer types. We show that the COL11A1-coexpressed gene set is highly conserved in these 13 cancer types, indicating that the fibroblast reaction to cancer cells is independent of the organ siteof-origin and of the transforming events within cancer cells. Finally, by combining drug target databases with cancer vs. normal tissue expression databases, we identify several potential therapeutic targets that should have high specificity for activated CAFs and minimal toxicity in normal tissues.
Materials and methods

Human tissues
Studies involving human tissue samples were approved by the Cedars-Sinai Institutional Review Board (IRB 15425). The samples included a tissue microarray from 42 patients with matched primary, metastatic, and recurrent ovarian cancer.
In situ hybridization
The RNA hybridization kit (RNAscope 2.0 FFPE Assay) and probes for COL11A1, the bacterial gene dapB (negative control), and the housekeeping gene HPRT (positive control), were from Advanced Cell Diagnostics, Inc. Formalin-fixed, paraffinembedded tissue section slides were processed by the Cedars-Sinai Biobank and Translational Research Core following the protocol provided with the RNAscope In Situ Hybridization kit from Advanced Cell Diagnostics, Inc. The slides were counterstained with Mayer's hematoxylin.
Immunohistochemistry
Immunohistochemical detection of αSMA was performed on formalin-fixed, paraffin-embedded tissue sections using the protocol provided with the prediluted asm-1 clone antibody from Leica Microsystems. Staining was done by the Cedars-Sinai Pathology Service on the Ventana Benchmark Ultra automated slide stainer. The staining was visualized using the Ventana OptiView DAB Detection System. The slides were counterstained with Mayer's hematoxylin.
In vitro co-culture experiments
The ovarian cancer cell lines OVCAR3-GFP, KURAMOCHI-GFP and OVSAHO-GFP were maintained in RPMI-1640 (Corning) supplemented with 10% fetal bovine serum (FBS) and 1x penicillin/streptomycin (Corning). Cell line authenticity was confirmed by Laragen using the short tandem repeat (STR) method. The immortalized normal ovarian fibroblasts INOF-tdTomato cell lines [34] were maintained in a 1:1 ratio of MCDB 105 (Sigma-Aldrich) and Medium 199 (GIBCO) with 10% FBS, 50 U/ ml penicillin and 50 μg/ml streptomycin. Immortalized normal ovarian fibroblasts and ovarian cancer cells were co-cultured in 1% FBS supplemented media (1:1:2 ratio of MCDB 105, Medium 199 and RPMI-1640) using 6-well plates, either by directly plating ovarian cancer cells (10 5 cells/well) onto a 70% confluent layer of normal ovarian fibroblasts or onto a 0.4 μm Transwell membrane. Media were replaced every 2 days. After 4 days of co-culture, GFP-labeled ovarian cancer cells and tdTomatolabeled fibroblasts were separated by FACS in PBS with 0.5% FBS. RNA extraction from fibroblasts and ovarian cancer cell lines was performed using the RNeasy Mini Kit (Qiagen) and reverse transcribed to cDNA using the Quantitect Reverse Transcription Kit (Qiagen). For qRT-PCR, 50 ng of cDNA was mixed with COL11A1 primers (Forward: 5′-GACTATCCCCTCTTCAGAACTGTTAAC-3′; Reverse: 5′-CTTCTATCAAGTGG TTTCGTGGTTT-3′) and the iQ SYBR-Green Supermix (BioRad) and run on the CFX96 Real-Time System (BioRad). Data were analyzed using the 2 -ΔCT method and normalized to INOF-tdTomato control to present the fold change ratios. All mRNA data were normalized to RPL32 expression (Forward: 5′-ACAAAGCACATGCTGCCCAGTG-3′; Reverse: 5′-TTCCACGATGGCTTTGCGGTTC-3′). The statistical analyses were performed using GraphPad Prism (version 6.0; GraphPad Software). The unpaired t test was used for data analyses.
Public database portals and dataset analyses
Data from public portals were used as provided by individual portals without additional processing or normalization, unless otherwise indicated. Box plots of COL11A1 expression in normal tissues and cancers were generated using the Gene Expression across Normal and Tumor tissue (GENT) portal (medicalgenome.kribb.re.kr/GENT) in which data from multiple datasets were processed and normalized as previously described [35] . COL11A1 expression level diagrams for inflammatory bowel disease, lung fibrosis, and cancers of the colon and lung were generated using the R2 MegaSampler public portal (hgserver1.amc.nl/cgi-bin/r2/ main.cgi). A description of the methods used for data processing and normalization is available through the portal. Survival z-scores for individual genes and cancer types were obtained from the PREdiction of Clinical Outcomes from Genomic Profiles (PRECOG) portal (precog.stanford.edu). Methods for calculating PRECOG z-scores have been published [36] . Ranking of the COL11A1-correlated genes in 13 TCGA carcinoma types was determined using data from individual cancer datasets that were processed by cBio Portal (cbioportal.org) as previously described [37] . KaplanMeier survival plots and plots of COL11A1 expression in individual molecular subtypes of ovarian carcinoma were generated using the ovarian cancer microarray gene expression database CSIOVDB (csibio.nus.edu.sg/CSIOVDB/CSIOVDB.html), which has been previously described [38] . The dataset for fibroblast and ovarian epithelial cell co-culture was imported from the Gene Expression Omnibus (ncbi.nlm.nih.gov/ geo). The Euclidean distance clustering analysis heatmap for the e-mtab-991 [39] and GSE40595 [40] datasets was generated using the public R2 GeneSet Clustering Analysis portal (hgserver1.amc.nl/cgi-bin/r2/main.cgi), which also describes methods that were used to process and normalize data from datasets included in the portal.
Results
COL11A1 is expressed in a subset of αSMA-positive CAFs and can be induced in normal fibroblasts by the presence of cancer cells
To determine if COL11A1 expression is associated with fibroblast activation, we used αSMA as a marker of activated CAFs [3] . Comparison of αSMA immunohistochemistry and COL11A1 in situ hybridization in a tissue microarray consisting of primary, metastatic and recurrent ovarian cancers from 42 patients showed that COL11A1 is expressed in a subset of αSMA+ CAFs (Fig. 1A) . Unlike αSMA, COL11A1 was not expressed in blood vessels (red arrows) or in fibroblasts surrounding the cancer (blue arrows) (Fig. 1A) .
In sections of metastatic ovarian cancer, we observed that COL11A1-positive cells are confined to the intratumoral and immediate peritumoral CAFs (Fig. 1B) , suggesting that COL11A1 expression may be induced by cues received from epithelial cancer cells. To test if cancer cells can induce COL11A1 expression in fibroblasts, we co-cultured immortalized normal ovarian fibroblasts (INOFs) with three different ovarian cancer cell lines (OVSAHO, OVCAR3, and KURAMOCHI). COL11A1 expression in INOFs was most strongly induced by direct co-culture with ovarian cancer cell lines although weak induction occurred by indirect co-culture on a Transwell membrane (Fig. 1C) . The induction of COL11A1 in fibroblasts in the presence of cancer cells was confirmed by analysis of the public expression dataset GSE52104 in which two types of presumptive cancer-associated fibroblast precursor cells, mesenchymal stem cells (MSCs) and immortalized normal ovarian fibroblasts (INOFs), were either cultured alone or co-cultured with normal ovarian surface epithelial cells (IOSE) or epithelial ovarian cancer cells (EOC) using a Transwell membrane [41] . COL11A1 mRNA was statistically significantly upregulated when MSCs and INOFs were co-cultured with EOC but not IOSE (Fig. 1D ), indicating that cancer cells have a greater capacity than normal cells to induce COL11A1 expression in fibroblasts.
COL11A1 is associated with cancer progression and poor survival COL11A1 mRNA expression has been associated with poor survival in ovarian cancer [32, 33] and kidney cancer [31] . To elucidate the underlying biology that could result in poor survival, we investigated its expression in ovarian and colon cancers. Using a comprehensively annotated microarray database for 3431 human ovarian cancers [38] , we show that increased expression of COL11A1 mRNA is associated with overall survival and disease-free survival ( Fig. 2A ) as well as with clinical and molecular parameters such as increased cancer stage and grade and mesenchymal molecular subtype (Fig. 2B) . The association of COL11A1 expression with poor survival is unlikely to be a manifestation of the total amount of stromal fibroblasts because a general marker of fibroblasts, vimentin (VIM), is not associated with poor survival in the same cohort of ovarian cancer patients (Table S1 ). The association of COL11A1 with adverse outcomes is also not restricted to ovarian cancer. We show that in 1820 colon cancers [42] , increased expression of COL11A1 mRNA is associated with poor disease-specific and disease-free survival as well as with clinical and molecular parameters, such as increased cancer stage and microsatellite instability and CMS4 (mesenchymal) molecular subtype (Fig. S1A, B) .
To systematically investigate an association between COL11A1 mRNA expression and survival in various solid and liquid cancers, we plotted COL11A1 z-score values as determined by the pancancer PREdiction of Clinical Outcomes from Genomic Profiles (PRECOG) analysis of~18000 cases in 166 cancer datasets [36] . In most epithelial cancers, COL11A1 expression was associated with poor survival (Fig. 3A) . Associations between expression of 43 collagen genes and survival z-scores in 12 common epithelial cancer types revealed that for the majority of collagens, increased expressions of mRNA were associated with poor survival, with COL11A1 having the strongest association (Fig. 3B) .
COL11A1 is among the most differentially expressed genes between cancers and corresponding benign tissues
In the Genotype-Tissue Expression (GTEx) project database [43] , COL11A1 mRNA is expressed at appreciable levels in transformed skin fibroblasts but not in non-transformed skin fibroblasts or other normal tissues (Fig. S2 ). Additional analyses of various expression datasets containing normal adult mouse and human tissues revealed that COL11A1 is expressed in cartilage and collagenproducing cells in the eye and brain, with negligible levels in most other tissues that have been profiled including mesenchymal stem cells in the bone marrow, muscle, and fat (data not shown).
Comparison of COL11A1 expression in 17931 cancers and 3503 normal tissues (U133Plus2 platform) and 9258 cancers and 4087 normal tissues (U133A platform) using the Gene Expression across Normal and Tumor tissue (GENT) portal [35] revealed that COL11A1 mRNA is elevated in most cancers in comparison to their corresponding normal tissues (Fig. 4A) . In some cancers, COL11A1 was ranked among the most statistically significant differentially expressed genes when cancer and its corresponding normal tissue were compared. For example, comparison of cancer and normal tissues in The Cancer Genome Atlas (TCGA) datasets for colon cancer and invasive breast cancer ranked COL11A1 as the first and third most differentially expressed gene, respectively (Fig. S3) .
As many collagens and collagen-remodeling genes are frequently upregulated in fibroblast activation associated with inflammation and fibrosis in the absence of cancer, use of these genes as therapeutic targets in cancer could be problematic. Analysis of expression profile datasets show that levels of COL11A1 mRNA in inflamed colonic tissue from inflammatory bowel disease and fibrotic lung tissues are not significantly different from those in corresponding unaffected colon and lung and that COL11A1 levels associated with colon inflammation and lung fibrosis are minimal and markedly different from those associated with colon and lung cancers (Fig. 4B) . In contrast, levels of ACTA2, the gene encoding the prototypical marker of myofibroblast differentiation, αSMA, is expressed at similar levels in cancers and inflamed or fibrotic tissues (Fig. 4B) .
A consistent set of genes is co-expressed with COL11A1 across different cancers
To better understand the biology of cancers with high levels of COL11A1, we identified genes that most closely correlate with COL11A1 mRNA expression in 13 TCGA datasets representing different cancer types. Spearman's rank correlations between COL11A1 and its co-expressed genes for each cancer type were calculated. The genes were then ranked based on the average correlation of each gene across the 13 cancer types. The top 195 correlated genes were selected based on an average correlation of >0.4 COL11A1-correlated genes were then ranked based on the average of the absolute correlation values (Table 1 and Table S2 ). The top 10% most highly correlated genes in each cancer type are highlighted in pink (Table 1) . Notably, COL11A1-correlated genes with high average correlation scores also tended to be among the top 10% highest scored genes in each cancer type (indicated in pink in Table 1 ). In contrast, the top 10% COL11A1-anticorrelated genes were not conserved across these cancer types (Table S3) . Some of the top ranked COL11A1-anticorrelated genes in individual cancer types were associated with normal functions of these organs suggesting that they may represent normal tissue or a noninvasive tumor component. For example, the ovarian cancer top 100 COL11A1-anticorrelated genes (Table S3 ) present in the GSE12172 ovarian cancer dataset were primarily expressed in ovarian tumors of low malignant potential (Fig. S4) .
Pan-cancer COL11A1-correlated genes are induced in CAFs
Consistent with the induced expression of COL11A1 in the in vitro co-culture model (Fig. 1D) , the average expression of the pancancer COL11A1-correlated gene set was significantly induced in mesenchymal stem cells and normal ovarian fibroblasts co-cultured with ovarian cancer cells but not with normal ovarian epithelial cells (Fig. S5) . Since epithelial cells were not profiled in this experiment, it is unknown if fibroblasts also induce expression of the pancancer COL11A1-correlated genes in epithelial cells. This is relevant because several of the 195 pan-cancer COL11A1-correlated genes have been shown to play a role in EMT [42] and malignant cells undergoing EMT have been proposed as one possible source of CAFs [44] . To determine if the pan-cancer COL11A1-correlated gene set is preferentially expressed in cancer cells undergoing EMT or in hostderived fibroblasts, we used the e-mtab-991 public transcription profile dataset of primary patient-derived colon cancers and their patient-derived xenografts (PDX) in nude mice [39] . Presumably, in PDX samples, fast-proliferating human cancer cells continued to grow in mice while slow-proliferating human CAFs were lost and eventually replaced by mouse fibroblasts, which can be distinguished from human cells by species-specific gene probes [39] . GeneSet clustering analysis showed that most of the pan-cancer COL11A1-correlated genes had diminished levels in PDX samples in comparison to primary cancers (Fig. 5A) , suggesting that the genes are enriched in the CAFs rather than in the cancer cells. However, it is also possible that the pan-cancer COL11A1-correlated genes are expressed in epithelial cells in primary colon tumors but become silenced upon adaptation of human cancer cells to the mouse microenvironment. Thus, we conducted GeneSet clustering analysis of the primary ovarian cancer dataset GSE40595 in which ovarian CAFs and epithelial cancer cells were isolated by laser-capture microdissection [40] . The pan-cancer COL11A1-correlated genes were preferentially expressed in CAFs in this dataset (Fig. 5B) .
In addition to CAFs, immune cells are a major component of the tissue microenvironment. To exclude the possibility that the pancancer COL11A1-correlated gene set represents immune cells in the tumor microenvironment, we used the expression profile of 230 mouse hematopoietic cell types generated by the Immunological Genome Project (ImmGen) compendium [45] . In addition to hematopoietic cell lineages, the dataset contains expression profiles of skin fibroblasts and fibroblasts residing in the thymus, lymph nodes, and spleen. The pan-cancer COL11A1-correlated gene set was highly represented in fibroblasts but not in hematopoietic cell lineages (Fig. 5C) .
CAFs have a different expression profile than normal fibroblasts. Moffitt and colleagues defined a 23-gene signature of 'normal stroma' and a 25-gene signature of 'activated stroma' [46] using nonnegative matrix factorization for virtual microdissection of primary and metastatic pancreatic ductal cancer samples into cell subsets with prognostic and biologic relevance. None of the 23 (0%) 'normal stroma' genes in contrast to 18 of 25 (72%) 'activated stroma' genes were present in the COL11A1-correlated gene set, respectively (Fig. 5D) , suggesting that the COL11A1-correlated gene set represents CAFs.
Biological processes associated with fibroblast activation in cancer
The remarkable uniformity of COL11A1-correlated genes across 13 different cancer types suggests involvement of these genes in common biological processes that are independent of the organ site and of the phenotypic and genetic diversity observed in individual cancer types. To gain insight into the biology of this conserved gene set, we conducted several analyses that identified overlap between the 195 pan-cancer COL11A1-correlated genes and genes in various datasets with characterized biological features. The Gene Ontology (GO) Biological Process (BP) analysis revealed that the pancancer COL11A1-correlated genes are primarily involved in extracellular matrix modification and collagen remodeling (Table S4) . Additionally, we used SABiosciences array gene tables, which consist of literature-based curated molecular pathways where each pathway was represented by 84 genes. Analysis of gene overlap between the pan-cancer COL11A1-correlated gene set and genes representative of 67 different pathways in SABiosciences arrays showed the largest overlap for pathways associated with extracellular matrix, GSE8671 (32) GSE16879 (133) GSE10616 (58) GSE38713 (43) GSE9452 (26) GSE2109 (315) GSE14333 (290) GSE17538 (232) GSE13294 (155) GSE21510 (148) GSE41568 (133) GSE8671 (32) GSE16879 (133) GSE10616 (58) GSE38713 (43) GSE9452 (26) GSE2109 (315) GSE14333 (290) GSE17538 (232) GSE13294 (155) GSE21510 (148) GSE41568 (133) GSE21369 (29) GSE24206 (23) GSE43580 (150) GSE2109 (121) GSE3141 (114) GSE33532 (100) GSE21369 (29) GSE24206 (23) GSE43580 ( Primary tumor (40) PDX ( fibrosis, osteogenesis, wound healing, EMT, cardiovascular disease, and transforming growth factor β (TGFβ) signaling (Table S5) . COL11A1-correlated gene set enrichment analysis of chemical and genetic perturbations (CGP) showed the most significant overlap with genes up-regulated in association with cancer invasiveness, advanced stage, stromal cell stemness, and epithelial-mesenchymal transition (EMT) ( Table S6 ). The uniformity of the COL11A1-correlated genes across different cancers might also indicate that these genes are regulated by a common mechanism. Ingenuity Pathway Analysis showed that transforming growth factor beta 1 (TGFB1) is the most strongly associated upstream regulator of the pan-cancer COL11A1-correlated genes (Table S7) .
COL11A1-correlated genes are associated with poor patient survival and represent potential therapeutic targets
To determine whether the pan-cancer COL11A1-correlated gene set is associated with patient survival in the~18,000 cases of liquid and solid malignancies in the PRECOG dataset [36] , we compared survival z-scores for the 195 pan-cancer COL11A1-correlated genes with the survival z-scores for all genes in the dataset. This analysis showed that expression of the pan-cancer COL11A1-correlated gene set is significantly associated with poor survival (Fig. 5E) .
Expression profile analyses have identified a mesenchymal molecular subtype of cancer associated with poor survival in multiple cancers including ovarian [47] , pancreatic [46] , gastric [48] and colon [49] . In colon cancer, it has been shown that the mesenchymal molecular subtype, which constitutes approximately 23% of colon cancers, has no significant enrichment for targetable mutations or copy number changes in candidate driver genes [49] . Even if future research identifies targetable events in cancer cells of the mesenchymal subtype, it is predicted that enrichment in CAFs and excessive ECM deposition will reduce therapeutic efficacy by creating a physical barrier for drug transport. Thus, simultaneous targeting of CAFs and cancer cells may be necessary for chemotherapeutic accessibility.
To identify therapies that preferentially target activated CAFs and spare normal tissues, we combined drug target searches with expression profile datasets in cancers and normal tissues. Ingenuity Pathway Analysis and searches of the Clinicaltrials.gov (clinicaltrials.gov) and ChEMBL [50] (ebi.ac.uk/chembl) databases revealed that, of the 195 pan-cancer COL11A1-correlated genes, 16 are targets of drugs used in clinical trials (Table S8 ) and 30 are targets of bioactive compounds (Table S9) .
To test whether any of the drug/bioactive compound target genes in Tables S8 and S9 are exclusively expressed in activated CAFs, we determined the expression levels of each gene in normal tissues in the GTEx database [43] and in normal vs. cancer tissues in the GENT database [35] . Additionally, to test whether selected genes were exclusively overexpressed in cancer tissues and not in non-cancer associated pathologies such as inflammation and fibrosis, we compared expression of these genes in normal tissues, inflamed/ fibrotic tissues and cancer tissues of the colon and lung. Unlike COL11A1, which has restricted expression in normal tissues (Fig. S2) and is highly elevated in cancer vs. normal tissues (Fig. 4A) and in cancer vs. inflamed/fibrotic tissues (Fig. 4B) most of the target genes were expressed at high levels in at least one normal tissue and/or exhibited equivalent expression levels in cancers vs. normal tissues, and cancers vs. inflamed/fibrotic tissues. One example of this pattern of expression is CTGF (Figs. S6 and S7) . However, FN1, MMP13, MMP14, FAP, LOX and COL1A2 exhibited restricted expression in normal tissues and elevated expression in cancer vs. normal tissues. One example of this pattern of expression is FAP (Figs. S8 and S9 ). Among FN1, MMP13, MMP14, FAP, LOX and COL1A2, FAP was also differentially expressed between inflamed/fibrotic tissues and cancer tissues although this difference in expression was not as prominent as for COL11A1 (compare Fig. S9B and Fig. 4B ).
Discussion
Whereas in the past most therapeutic approaches have focused on the cancer cell and its genetic alterations, it is becoming apparent that the microenvironment plays an equally important role in cancer evolution. We now recognize that the cancer stroma not only serves as a scaffold for tissue organization and integrity but also provides key biomechanical and molecular signals that can affect various aspects of cancer growth and biology, including proliferation, survival, metabolism, stem cell fate, and response to chemotherapy [51, 52] . As the genetically stable subpopulations of the cancer microenvironment are increasingly recognized as potentially effective therapeutic targets, a comprehensive definition of their molecular characteristics will be a prerequisite for the development of more precise and less toxic therapies. Currently, there are no reliable methods to distinguish activated CAFs from non-activated CAFs, which although frequently abundant within cancers do not necessarily contribute to adverse outcome. We identified COL11A1 among the top differentially expressed genes in multiple cancer types when cancer tissues and their corresponding normal tissues were compared. We showed that an increase in COL11A1 expression is associated with progression and poor survival in most cancer types. COL11A1 is a particularly attractive therapeutic target because of its restricted expression in normal tissues and non-cancer conditions, such as inflammation and fibrosis.
The identification of a highly conserved set of genes associated with COL11A1 expression in breast, lung, pancreas, stomach, urinary bladder, colon, thyroid, cervix, head and neck, thyroid, ovary, and prostate cancers was somewhat surprising in light of the genetic and phenotypic diversity among these cancer types. The conserved expression signature indicates that the reaction of stromal tissues to invading epithelial cancer cells may be similar regardless of the organ of origin or genetic alterations. This has significant implications for the development of pan-cancer therapeutic strategies. Our analysis of potential upstream regulators of the pancancer COL11A1-correlated genes revealed TGFB1 as the most likely candidate. Dysregulation of TGFβ signaling is recognized as the main driver of fibroblast activation and represents the most logical therapeutic target [53] . In immortalized normal ovary fibroblast cell culture, recombinant TGFB1 has been shown to upregulate expression of COL11A1 and several other COL11A1-correlated genes; this effect was abrogated by the TGFβ receptor inhibitor A83-01 [32] . However, the pleiotropic nature of TGFβ signaling carries the risk of adverse effects in patients [54] . In order to abrogate fibroblast activation without the negative effects of pan-TGFβ therapy, it will be necessary to design therapies for more specific targets.
Sixteen of the 195 pan-cancer COL11A1-correlated genes are targets of drugs in clinical trials. These targets include CTGF, a matricellular protein involved in myofibroblast formation in cancer as a binding factor of fibronectin and a downstream mediator of TGFβ. A clinical trial (clinicaltrials.gov; NCT02210559) is currently enrolling patients with unresectable pancreatic cancer to test a combination of conventional chemotherapy and FG-3019, the human monoclonal antibody that interferes with the action of CTGF. Our expression analyses, consistent with the published literature (reviewed in Ref. [55] ), show that CTGF is expressed at similar levels in normal tissues and cancers and therefore unlikely to be a safe therapeutic target for cancer treatment. In contrast, targets such as FN1, FAP, MMP13, LOX and COL2A1 are markedly increased in cancer/ inflammation/fibrosis compared to normal tissues and are thus predicted to have a better safety profile than agents targeting CTGF. Our assessment is consistent with the published moderate and reversible toxicity of the FN1-targeting monoclonal antibody-cytokine fusion protein L19-IL2, which is in a phase I/II study for patients with solid cancers (clinicaltrials.gov; NCT01058538) [56, 57] . Our expression analyses show that one of the targets of bioactive compounds, FAP, has low expression in normal tissues and also lower expression in inflamed/fibrotic tissues than in cancer. Yet, this difference in expression may not be sufficient for specific targeting of activated CAFs as studies in mouse models have shown that depletion of the FAP+ stroma can induce toxicity due to expression of FAP in the mesenchymal cells of bone marrow, muscle and adipose tissue [58, 59] . Future efforts to specifically target activated CAFs can be improved by designing novel therapies to target genes that exhibit restricted expression in nonmalignant tissues. When considering COL11A1 as a cancer-specific biomarker and therapeutic target, it is important to note that several normal tissues express COL11A1. The potential side effects of COL11A1 targeting can be predicted based on the phenotypes of mice and humans expressing mutant nonfunctional forms of COL11A1. A homozygous truncating mutation of COL11A1 in mice results in poorly formed cartilage [60] , while human COL11A1 mutations are associated with articular hypermobility, dermal hyperelasticity and widespread tissue fragility [61] . Of note, these collagenopathies are associated with the absence of COL11A1 function throughout development and are unlikely to manifest upon transient targeting of COL11A1 in adults. Additionally, since COL11A1 and many of the pan-cancer COL11A1-coexpressed genes have multiple tissue-specific mRNA splicing isoforms, it will be valuable for future targeting purposes to determine if any mRNA isoforms are specifically expressed in activated CAFs [62] .
